Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 4Thoracic 2Plasma cell 2Head & Neck 2Gastrointestinal 2CNS 2NET 1Lymphoid 1Gynecologic 1Genitourinary 1Endocrine 1Breast 1

Conditions

Multiple Myeloma 495Lymphoma 52Recurrence 50Neoplasms, Plasma Cell 49Immunoglobulin Light-chain Amyloidosis 43Neoplasms 35Lymphoma, Non-Hodgkin 35Leukemia 34Hematologic Neoplasms 32Myelodysplastic Syndromes 28Smoldering Multiple Myeloma 27Leukemia, Myeloid, Acute 26Leukemia, Plasma Cell 23Precursor Cell Lymphoblastic Leukemia-Lymphoma 21Monoclonal Gammopathy of Undetermined Significance 18Hodgkin Disease 18Leukemia, Lymphocytic, Chronic, B-Cell 17Amyloidosis 17Lymphoma, B-Cell 15Breast Neoplasms 14Ovarian Neoplasms 12Paraproteinemias 11Myeloproliferative Disorders 10Colorectal Neoplasms 10Primary Myelofibrosis 9Melanoma 9Lymphoma, Follicular 9Infections 9Prostatic Neoplasms 8Lymphoproliferative Disorders 8

Interventions

selinexor 1repotrectinib 1pazopanib 1Suspensions 1Proton Therapy 1Ifosfamide 1Doxorubicin 1Capsules 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Solitary Fibrous Tumors × Plasma cell × Clear all
NCT06239272 2026-05-19

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

St. Jude Children's Research Hospital

Phase 1/2 Recruiting
139 enrolled
Plasma cellSarcoma

Histiocytoma, Angiomatoid Fibrous, Chondrosarcoma, Extraskeletal Myxoid, Fibrosarcoma, Glomus Tumor, Granuloma, Plasma Cell, Hemangiosarcoma, Liposarcoma, Myoepithelioma, Sarcoma, Osteosarcoma, Disorders of Sex Development, Granular Cell Tumor, Neoplasms, Adipose Tissue, Liposarcoma, Myxoid, Dermatofibrosarcoma, Sarcoma, Clear Cell, Smooth Muscle Tumor, Nerve Sheath Neoplasms, Neurofibrosarcoma, Hemangioendothelioma, Epithelioid, Vascular Neoplasms, Solitary Fibrous Tumors

NCT04094610 2025-11-19

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Turning Point Therapeutics, Inc.

Phase 1/2 Recruiting
75 enrolled
CNSLymphoidPlasma cellSarcoma

Glioblastoma, Glioma, Granuloma, Plasma Cell, Lymphoma, Neoplasm Metastasis, Sarcoma, Lymphoma, Large-Cell, Anaplastic, Solitary Fibrous Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡